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a b s t r a c t
T cell-receptor transgenic NOD8.3 mice provide a model for spontaneous type 1 diabetes development.
Infection of 5 week-old NOD8.3 mice with Rhesus monkey rotavirus (RRV) accelerates the onset of their
diabetes. This acceleration requires virus replication and relates to the presence and level of serum anti-
rotavirus antibodies, but the role of individual RRV genes is unknown. Here we assessed the importance
for diabetes acceleration of the RRV genes encoding VP4 and VP7, by infecting NOD8.3 mice with
parental and reassortant rotaviruses. Diabetes was accelerated by reassortant rotaviruses containing RRV
VP7 on a UK rotavirus genetic background, but not by parental UK or a UK reassortant containing RRV
VP4 without VP7. Diabetes acceleration by reassortant rotaviruses containing RRV VP7 depended on the
development of a high serum anti-rotavirus antibody titer. This study shows that VP7, together with an
elevated anti-rotavirus antibody response, contributes to the acceleration of diabetes onset by RRV.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Rotavirus infection is associated with progression towards type
1 diabetes in children (Honeyman et al., 2000; Lempainen et al.,
2012). Wild-type non-obese diabetic (NOD) mice and T cell-
receptor transgenic NOD8.3 mice spontaneously develop type
1 diabetes and provide models for the human disease. NOD8.3
mice contain a large population of CD8þ T cells speciﬁc for islet-
speciﬁc glucose-6-phosphatase catalytic subunit-related protein
(IGRP), an important islet autoantigen in humans and mice. Thus,
they progress more rapidly to diabetes than NOD mice (Lieberman
et al., 2003; Verdaguer et al., 1997). While NOD8.3 and NOD females
show a diabetes penetrance of 60–80%, diabetes develops in 30–50%
of NOD8.3 males but only 10–20% of NOD males (Graham et al.,
2008; Solomon and Sarvetnick, 2004; Verdaguer et al., 1997).
Therefore, studies of NOD8.3 females and males combined, or of
individual sexes, can be similarly informative.
Diabetes onset is accelerated by oral infection of 12 week-old
female NOD mice, or 5 week-old male or female NOD8.3 mice, with
Rhesus monkey rotavirus RRV (Graham et al., 2008). Similarly,
diabetes onset in NOD mice is more rapid following infection with
murine EM rotavirus (Graham et al., 2008). Diabetes acceleration in
NOD8.3 mice requires RRV replication and relates to the presence
and level of serum anti-rotavirus antibodies (Graham et al., 2008;
Pane et al., 2013). Infection of NOD8.3 mice with a 100-fold lower
dose of RRV leads to reduced virus replication and anti-rotavirus
antibody titers. Despite this, diabetes onset is accelerated by this low
RRV dose, suggesting that diabetes acceleration in NOD8.3 mice can
occur even when antibody titers are low (Graham et al., 2008; Pane
et al., 2013). As infection with porcine rotavirus CRW-8 does not
accelerate diabetes onset in 12 week-old female NOD mice, the
rotavirus ability to modulate murine diabetes appears to be strain-
speciﬁc.
Most heterologous rotaviruses show host range restriction.
However, RRV can replicate comparably to homologous rotavirus
in some host species (Ciarlet et al., 1998; Ciarlet et al., 2000). In
addition, the extent of extra-intestinal spread by RRV and mouse
rotavirus in infant mice is similar (Fenaux et al., 2006). These RRV-
speciﬁc features may help explain why RRV, but not CRW-8,
accelerates diabetes similarly to murine EM rotavirus (Graham
et al., 2008; Pane et al., 2013). The RRV outer capsid proteins VP4
and VP7 have been linked to virulence, replicative ability, neutraliz-
ing antibody responses and host range restriction (Ciarlet et al.,
1998; Graham et al., 2003; Ludert et al., 1996; Ludert et al., 2002).
Therefore, we assessed the importance of the genes encoding VP4
and VP7 for diabetes acceleration, taking advantage of the segmen-
ted double-stranded RNA rotavirus genome and the resulting ability
to generate reassortant rotaviruses with mixed genetic parentage.
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Reassortant rotaviruses were assessed for their ability to induce an
anti-rotavirus antibody response, virus excretion and accelerated
diabetes onset in NOD8.3 mice. Analogous approaches have been
used previously to identify RRV VP4 as a biliary atresia determinant
(Feng et al., 2011; Wang et al., 2011).
Results
Anti-rotavirus antibody titers and virus excretion in NOD8.3 mice
infected with parental and reassortant rotaviruses
Antibody titers and virus excretion were measured following
infection of NOD8.3 mice with wild-type rotaviruses (RRV, UK,
SA11 and CRW-8) and RRVUK reassortant strains (28/1, 12/1 and
9-8-1). The total anti-rotavirus immunoglobulin end-point titer
was determined in mouse serum at day 14 post-infection. Anti-
rotavirus antibodies were undetectable in mock-inoculated mice.
RRV infection elicited antibody responses in 100% (24/24) of mice,
as before (Graham et al., 2008). UK, SA11, CRW-8, 28/1, 12/1 and
9-8-1 induced antibodies in 62% (13/21), 73% (11/15), 48% (27/56),
82% (23/28), 70% (21/30) and 70% (14/20) of mice, respectively.
All antibody titers were similar, except that UK and CRW-8 indu-
ced signiﬁcantly lower titers than RRV (Fig. 1A; p¼0.0020 and
po0.0001, respectively). In contrast to parental RRV and UK, the
reassortant rotaviruses induced a wider range of serum anti-
rotavirus antibody titers. The antibody titers resulting from reas-
sortant rotavirus infection in adult mice have not been reported
before to our knowledge, and the reason for this difference in titer
range is unknown.
Mouse excretion of rotavirus antigen and infectious virus was
evaluated on days 1–4 post-infection, as previous studies showed
this is the period when excretion of RRV by NOD8.3 mice is
detectable (Graham et al., 2008). No virus was excreted by mock-
inoculated mice. Consistent with the 45% shedding reported pre-
viously (Graham et al., 2008), 38% (9/24) of NOD8.3 mice excreted
RRV, 13% (3/24) on multiple days (Fig. 1B). After UK inoculation, 29%
(6/21) of mice excreted virus, 10% (2/21) on multiple days. SA11
excretionwas detected in 40% (4/10) of mice on day 1 only. Following
CRW-8 infection, 11% (4/38) of mice excreted virus, each on a single
day post-infection. After infection with 28/1, 38% (8/21) of mice
excreted virus, with no mice excreting on multiple days. Mice given
12/1 showed a 76% (13/17) excretion rate, and 6% (1/17) shed virus on
multiple days. Similarly, 65% (8/12) of mice shed 9-8-1, 25% (3/12) on
multiple days. No differences in virus antigen levels were observed
between virus inoculum groups and antibody titer did not relate to
the degree of virus excretion for any rotavirus inoculum.
Overall, only RRV induced a rotavirus-speciﬁc antibody response
in all inoculated mice. A substantial proportion of mice responding
to a reassortant virus produced antibody titers at least as high as
those induced by RRV infection. Also, reassortants 9-8-1 and 12/1,
which contain RRV VP7, were more frequently excreted than the 28/1
reassortant containing RRV VP4. This suggests a potential role for RRV
VP7 in increasing virus excretion by NOD8.3 mice, but does not rule
out a role for other RRV genes. In individual mice, increased virus
excretion was not associated with higher antibody titers.
Infection with RRV, but not UK, SA11 or CRW-8 rotaviruses,
accelerated diabetes onset in NOD8.3 mice
Rotavirus-inoculated NOD8.3 mice producing anti-rotavirus anti-
bodies were monitored for diabetes onset in parallel with mock-
inoculated mice. RRV infection accelerated diabetes onset up to 12
weeks of age (Fig. 2A; p¼0.017), as before (Graham et al., 2008).
In contrast, diabetes development was unaltered by UK (Fig. 2A;
p40.05). Although no signiﬁcant difference in diabetes development
up to 20 weeks of age was observed following CRW-8 infection
(p40.05), diabetes progression potentially may have stalled com-
pared with controls from 13 to 17 weeks of age. This effect was
unrelated to mouse sex, as when analyzed separately both males and
females showed a possible delay in diabetes onset compared with
their sex-matched controls (data not shown). In addition, this
difference was independent of antibody response, as diabetes rates
were similar between mice with reciprocal titers of Z1600 or r800
(data not shown). Similarly, from 12 to 18 weeks of age the diabetes
incidence in SA11-infected mice (all females) plateaued, while mock-
inoculated female controls continued to develop diabetes (Fig. 2B).
Females were used as we had seen no sex bias with RRV, UK and
CRW-8 studies, and females show a slightly higher diabetes incidence
than males. Again, neither diabetes incidence nor progression to
diabetes was signiﬁcantly reduced in the SA11-infected mice during
this period (p40.05). It remains possible that SA11 and CRW-8
infections may delay diabetes onset in these mice, although the
mechanism involved is unclear. However, virus excretion was least in
mice infected with SA11 or CRW-8 (Fig. 1B), likely indicating reduced
intestinal replication, which may favor a tolerogenic rather than
Fig. 1. Rotavirus-speciﬁc antibody responses and virus excretion in rotavirus-
infected NOD8.3 mice. (A) Serum anti-rotavirus antibody titers induced by infection
of NOD8.3 mice with rotavirus strains RRV (14 females, 10 males), UK (10 females,
11 males), SA11 (15 females), CRW-8 (23 females, 33 males), 28/1 (14 females,
14 males), 12/1 (15 females, 15 males) and 9-8-1 (20 females). Serum was collected
at day 14 after rotavirus infection (2107 FCFU). Total anti-rotavirus immunoglo-
bulin levels were determined by ELISA using homologous rotavirus antigen. Data
from mice lacking an antibody response (reciprocal titer o50) are not included.
Bars indicate the geometric mean titer. (B) Proportion of mice excreting infectious
rotavirus and/or rotavirus antigen. Stools collected on each of days 1 to 4 post-
infection from either the majority (SA11, CRW-8, 28/1, 12/1, 9-8-1) or all (RRV, UK)
infected NOD8.3 mice were processed as 10% (wt/vol) homogenates for virus
detection by culture in MA104 cells and ELISA, as before (Graham et al., 2008).
Mouse numbers studied for each virus are indicated. Inoculated mice comprised
17 females and 21 males (CRW-8), 9 females and 12 males (28/1) and 11 females
and 6 males (12/1).
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pro-inﬂammatory immune response. A tolerogenic response would
be expected to delay diabetes, as seen in RRV-infected infant NOD
mice (Webster et al., 2013). Overall, only RRV accelerated diabetes
development in adult NOD8.3 mice, allowing the evaluation of the
role of VP4 and VP7 in diabetes modulation using reassortant
rotaviruses with mixtures of RRV and UK genes.
The presence of RRV VP7 on a UK genetic background led to
accelerated diabetes development in NOD8.3 mice that had
responded with high anti-rotavirus antibody titers
As reciprocal antibody titers to reassortants showed a broad
range (Fig. 1A), mice were segregated into those with antibodies
above (hiAb, Z1600) or below (loAb, r400) the geometric mean
for analysis of their diabetes development. Infection with reassor-
tant 28/1 containing RRV VP4 did not affect diabetes development,
irrespective of hiAb or loAb status (Fig. 3A, B; p40.05). Mice given
reassortant 12/1 containing RRV VP7 showed accelerated diabetes
onset up to 12 weeks of age (Fig. 3A, p¼0.0059), and increased
diabetes incidence at this age (Fig. 3A, p¼0.0045). Notably, diabetes
was signiﬁcantly accelerated at up to 20 weeks of age in the hiAb
group given 12/1, but not the loAb group (Fig. 3B, p¼0.040 and
p40.05, respectively). Furthermore, diabetes incidence at 12 weeks
of age was signiﬁcantly elevated only in this hiAb group
(p¼0.0057). Thus, mice responding to 12/1 with hiAb accounted
for most of the diabetes acceleration by 12/1. Mice given VP7
monoreassortant 9-8-1 developed diabetes at a similar rate to
controls (Fig. 3C, p40.05). However, a possible trend for accelerated
diabetes was observed in hiAb mice given 9-8-1 compared with
controls (Fig. 3D, p¼0.090), and diabetes was signiﬁcantly acceler-
ated up to 12 weeks of age in these hiAb mice over loAb mice given
9-8-1 (Fig. 3D, p¼0.050). Overall, reassortant rotaviruses containing
RRV VP7, but not RRV VP4, induced diabetes acceleration in NOD8.3
mice. This indicates that RRV VP7 plays a role in the induction of
diabetes acceleration by RRV.
Discussion
This study has shown that the RRV outer capsid protein VP7
confers on UK rotavirus the ability to accelerate type 1 diabetes
development in NOD8.3 mice when associated with the develop-
ment of a strong serum anti-rotavirus antibody response.
Although reassortant rotaviruses containing RRV VP7 were more
commonly excreted, this was not associated with anti-rotavirus
antibody titer or mouse age at diabetes onset. To our knowledge,
this study is the ﬁrst to directly identify a role for a speciﬁc viral
protein in the modulation of type 1 diabetes by any virus.
The lower reciprocal antibody titers generated by UK infection
could explain the inability of UK to modulate diabetes. However, we
previously demonstrated that NOD8.3 mice with similarly low titers
following RRV infection can show diabetes acceleration (Pane et al.,
2013). In addition, SA11 induced high reciprocal antibody titers but
did not accelerate diabetes onset. Thus, antibody level alone does not
predict whether or not a particular rotavirus can accelerate diabetes
in NOD8.3 mice. This was further conﬁrmed by our reassortant
studies, as 28/1 did not affect diabetes development, irrespective of
antibody level. However, those reassortants capable of accelerating
diabetes were more effective when they induced high antibody titers.
Diabetes acceleration by RRV in NOD mice is not characterized by
extensive immune cell activation within the small intestine (Pane
et al., 2014b). Instead, diabetes acceleration is associated with immune
cell activation and pro-inﬂammatory cytokine expression in regional
lymph nodes, pancreas and spleen (Graham et al., 2008; Pane et al.,
2014b). The level of the serum antibody response most probably
reﬂects the scale of the systemic immune response. This may explain
why acceleration by RRV correlates with antibody titer, and accelera-
tion by reassortant rotaviruses depends on a high antibody titer. The
observation that a low antibody response to RRV does not preclude
diabetes acceleration (Pane et al., 2013) may seem contradictory to this
hypothesis. However, it is reasonable to assume that parental RRV has
a greater capacity to induce diabetes acceleration than its reassortants.
Even when RRV VP7 is present, it is unlikely that reassortant
rotaviruses will exhibit the ﬁtness of parental RRV. In terms of virus
dose, this could explain why 2104 FCFU of RRV is sufﬁcient to
induce diabetes acceleration, whereas 2107 FCFU is probably
necessary for diabetes acceleration by reassortant rotaviruses contain-
ing RRV VP7. Virus excretion was more common for these diabetes-
accelerating rotaviruses, suggesting that RRV VP7 may contribute to
intestinal replication. However, this was independent of antibody level
in individual mice, suggesting stool virus shedding is unrelated to
diabetes modulation. Thus, it is unlikely that intestinal replication
relates to the ability to accelerate diabetes.
Although we demonstrated that RRV VP7 is important for diabetes
acceleration by RRV in NOD8.3 mice, reassortant 12/1 induced
diabetes acceleration more effectively than 9-8-1. Thus, a role for
RRV VP2 cannot be completely ruled out. VP2 is important for VP1 and
VP3 encapsidation and viral polymerase activity (McDonald and
Patton, 2011; Zeng et al., 1998). Possibly, co-segregation of RRV VP2
Fig. 2. Ability of infection with monkey, bovine and porcine rotaviruses to
modulate type 1 diabetes development in NOD8.3 mice. Mice that received the
indicated rotavirus (2107 FCFU), and showed a reciprocal serum antibody titer to
homologous virus of 450 by ELISA at 14 days post-infection, were monitored for
diabetes development in parallel with control mice given virus diluent (mock).
Although both sexes begin developing diabetes at the same age (6 weeks), males
show a slightly lower diabetes incidence than females (Graham et al., 2008).
(A) Mice were given RRV (14 females, 10 males), UK (6 females, 7 males), CRW-8 (10
females, 17 males) or virus diluent (46 females, 39 males). Data from mice given
virus diluent have been published previously (Pane et al., 2013). (B) Females were
inoculated with SA11 or virus diluent.
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with VP7 might increase replicative ﬁtness in NOD8.3 mice. VP7 but
not VP2 is implicated in host species restriction (Ciarlet et al., 1998;
Hoshino et al., 1995; Mori et al., 2003). Although neither RRV VP7 nor
RRV VP2 is a murine biliary atresia determinant, VP7 might enhance
biliary tissue infection (Feng et al., 2011; Wang et al., 2011). As we
focussed primarily on the roles of VP4 and VP7, it remains possible
that RRV genes not evaluated here also may contribute to diabetes
acceleration. The ability to produce monoreassortants for each RRV
gene on a UK genetic background is limited, as reassortant rotavirus
generation is to some extent random while generally involving gene
co-segregation. In addition, it is impractical to produce diabetes curves
with hiAb mice from a sufﬁciently large panel of reassortants to
evaluate the role of every RRV gene. Nevertheless, we have shown an
important role for the VP7 (and possibly VP2) gene in diabetes
acceleration.
RRV and other rotaviruses induce type 1 interferon-mediated
bystander activation of mouse lymphocytes ex vivo (Pane et al.,
2014a). However, this activation is independent of rotavirus strain
and does not correlate with the ability to accelerate diabetes.
Rather, RRV acceleration of diabetes in NOD8.3 mice is associated
with RRV spread to regional lymph nodes, increased MHC class I
expression on islet β cells and elevated interferon-γ expression by
splenic CD8þ T cells (Graham et al., 2008; Pane et al., 2013; Pane et
al., 2014b). Analysis of these properties after reassortant rotavirus
infection is not feasible because most changes occur prior to
substantial anti-rotavirus antibody production. Not all reassortant-
inoculated NOD8.3 mice produce an antibody response, and titers
vary considerably (Fig. 1A). As the presence and level of antibody
response is important for diabetes acceleration in this model,
interpretation of data from such studies is problematic.
Diabetes acceleration may be independent of rotavirus VP7
(G) serotype, as RRV, EM, SA11 and CRW-8 are G3 but only RRV and
EM accelerate diabetes onset. We derived and compared relevant VP7
sequences using established methods (Holloway et al., 2009).
All reassortant VP7 sequences were identical to their parental strains.
Our RRV, UK, EM, SA11 and CRW-8 VP7 sequences were iden-
tical to the corresponding Genbank sequences VGXRRR, AFC40994,
BAA23163.1, VP_002302222.1 and P32546, respectively. Only a single
VP7 aa (at position 49) was conserved between RRV and EM but not
shared with UK, SA11 and CRW-8, possibly implicating this residue in
diabetes acceleration by rotavirus. Interestingly, aa 49 is located in the
VP7 variable region VR-3 outside neutralisation epitope regions (Green
et al., 1987; Kirkwood et al., 1993; Lazdins et al., 1995; Richardson et al.,
1984). It is adjacent to the signal peptide cleavage site and within the
signal sequence for VP7 retention in the endoplasmic reticulum
(Stirzaker and Both, 1989). Possibly, aa 49 may inﬂuence VP7 signal
sequence cleavage or otherwise affect rotavirus replication and trop-
ism. This residue also is sited in a predicted peptide mimic of a CD4þ T
cell epitope in human islet autoantigen-2 (IA-2). Human CD4þ T cells
stimulated by this IA-2 peptide can be restimulated with a VP7
peptide (aa 40–49) (Honeyman et al., 2010). However, molecular
mimicry is unlikely in mice, as aa 49 in RRV and EM differs from
the corresponding residue in this VP7 peptide, and MHC II peptide
presentation differs between mice and humans. Indeed, our previous
Fig. 3. Effect of infection with reassortant rotaviruses on diabetes development in NOD8.3 mice. Mice that received the indicated rotavirus (2107 FCFU), and showed a
reciprocal serum antibody titer to homologous virus of 450 by ELISA at 14 days post-infection, were monitored for diabetes development in parallel with control mice given
virus diluent (mock). These experiments overlapped temporally with the RRV and UK studies presented in Fig. 2A. (A) Mice were given 28/1 (11 males, 12 females), 12/1 (10
males, 11 females) or virus diluent (29 males, 30 females). (B) Diabetes curves for mice in A after their stratiﬁcation by high (hiAb, Z1600) or low (loAb, r400) anti-
rotavirus antibody titer. Mice given 28/1 comprised 8 males and 5 females with hiAb, and 3 males and 7 females with loAb. Mice given 12/1 comprised 4 males and 7 females
with hiAb, and 6 males and 4 females with loAb. (C) Diabetes curves for females inoculated with 9-8-1 or virus diluent. (D) Diabetes curves for mice in C after stratiﬁcation by
antibody titer as above.
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studies with IGRP-speciﬁc CD8þ T cells failed to show molecular
mimicry between the IGRP epitope recognized by these T cells and a
known RRV VP7 CD8þ T cell epitope (Pane et al., 2014b).
Advances on current technology, allowing the production of
rotaviruses with altered VP7 sequences and efﬁcient replicative
ability in mice, might facilitate the demonstration of the roles of
speciﬁc VP7 functions in this process. Furthermore, an analogous
approach might be adopted for other viruses with segmented
genomes, such as inﬂuenza virus, which have been linked to type
1 diabetes development (Ferreira et al., 2014; Nenna et al., 2011;
Valdes et al., 2013; Xia et al., 2014). Such experiments may help
establish a link between speciﬁc viral functions and an ability to
modulate type 1 diabetes.
Materials and methods
Viruses and cells
Monkey rotaviruses RRV and SA11, bovine rotavirus UK, porcine
rotavirus CRW-8 and reassortant rotaviruses 28/1, 12/1 and 9-8-1
(Feng et al., 2009) were ampliﬁed in MA104 cells, puriﬁed by
glycerol gradient ultracentrifugation and their infectious titers in
ﬂuorescent cell-forming units (FCFU)/ml determined as described
previously (Fleming et al., 2014; Hewish et al., 2000; Holloway and
Coulson, 2006). The reassortants possess a UK genetic background
and the following RRV genes- 28/1: VP3, VP4 and NSP5/6; 12/1:
VP2, VP7 and NSP5/6; and 9-8-1: VP7 (Feng et al., 2009; Kalica
et al., 1983). Rotavirus gene origins were conﬁrmed by RNA
electrophoretic migration, and VP4 and VP7 gene sequencing, as
before (Dyall-Smith and Holmes, 1984; Holloway et al., 2009).
Mouse inoculation
T cell-receptor transgenic NOD8.3 mice were obtained, bred and
housed in individually-ventilated cages under speciﬁc pathogen-free
conditions in the Biological Research Facility of the Department of
Microbiology and Immunology at the University of Melbourne as
before (Pane et al., 2013). All procedures were conducted in accor-
dance with protocols approved by the Animal Ethics Committee of
the University of Melbourne. NOD8.3 mice were orally inoculated at
5 weeks of age with virus diluent (mock) or 2107 FCFU of puriﬁed
RRV, UK, SA11, CRW-8 or reassortant rotaviruses 28/1, 12/1 and 9-8-1,
as before (Graham et al., 2008; Pane et al., 2013).
Rotavirus antibody, antigen and culture assays
Total serum anti-rotavirus immunoglobulin (IgG, IgA and IgM)
levels at 14 days post-inoculation were determined by ELISA using
homologous rotavirus and cell control antigen produced from
mock-infected MA104 cells, as before (Graham et al., 2007; Pane
et al., 2013). Log10-transformed antibody titers were analyzed by
t-test. Rotavirus antigen was assayed in stools collected from most
mice on days 1–4 post-infection by ELISA as before (Graham et al.,
2007; Pane et al., 2013). For detection of infectious rotavirus, stool
homogenates were cultured with MA104 cells prior to detection of
rotavirus antigen by ELISA. Mice were considered to be excreting
rotavirus on any given day if virus antigen and/or infectious virus
was detectable in their stools. Controls included stools from mock-
inoculated mice.
Mouse diabetes monitoring
Rotavirus-inoculated NOD8.3 mice producing anti-rotavirus
antibodies were monitored for diabetes onset in parallel with
mock-inoculated mice, as before (Graham et al., 2008; Pane et al.,
2013). Approximately equal numbers of male and female mice
infected with RRV, UK, CRW-8, 28/1 and 12/1 were studied.
However, only female mice were infected with SA11 and 9-8-1.
This sex difference is not expected to affect the outcome of virus
infection, as the ability of RRV to induce diabetes acceleration in
NOD8.3 mice is independent of sex (Graham et al., 2008). Mice
were considered diabetic when blood glucose levels were
42.40 mg/ml on two occasions, 2 days apart. Diabetes curves
and incidence were evaluated with log-rank (Mantel-Cox) and
Fisher's exact test, respectively.
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